LifeMine Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- LifeMine Therapeutics's estimated annual revenue is currently $28.3M per year.
- LifeMine Therapeutics received $55.0M in venture funding in September 2017.
- LifeMine Therapeutics's estimated revenue per employee is $193,750
- LifeMine Therapeutics's total funding is $120M.
Employee Data
- LifeMine Therapeutics has 146 Employees.
- LifeMine Therapeutics grew their employee count by -12% last year.
LifeMine Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-founder & COO | Reveal Email/Phone |
2 | Head Fermentation | Reveal Email/Phone |
3 | EVP and Head Discovery & Translational Biology | Reveal Email/Phone |
4 | AVP, Global Controller | Reveal Email/Phone |
5 | VP, Translational Bioinformatics | Reveal Email/Phone |
6 | Head Fermentation | Reveal Email/Phone |
7 | EVP, Head CMC | Reveal Email/Phone |
8 | SVP and Head Chemistry | Reveal Email/Phone |
9 | VP, Genomics, Multiomics & AI | Reveal Email/Phone |
10 | VP Synthetic Biology, Bioengineering & Bioprocess | Reveal Email/Phone |
LifeMine Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is LifeMine Therapeutics?
LifeMine Therapeutics is pioneering a genomically-enabled drug discovery approach integrating advanced life science and computational technologies to elucidate human biology and create sophisticated therapeutics that attack the fundamental drivers of serious human diseases. LifeMine will access new drug modalities by conducting the first industrial-scale operation exploiting small molecule evolution in fungi to discover game-changing therapeutics. The initial focus will be on immune modulators, metabolic effectors, and cell differentiators. This platform is expected to provide multiple first- and best-in-class therapeutics in succession, and to continue delivering these for years to come. Founder & CEO: Greg Verdine, Erving Professor at Harvard University and Harvard Medical School. Founder of Gloucester Pharmaceuticals (acquired by Celgene), Enanta Pharmaceuticals (NASDAQ: ENTA), Eleven Biotherapeutics (NASDAQ: EBIO), Tokai Pharmaceuticals (NASDAQ: TKAI), WaVe Life Sciences (NASDAQ: WVE), Warp Drive Bio, Aileron Therapeutics, and the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy.
keywords:N/A
$120M
Total Funding
146
Number of Employees
$28.3M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
LifeMine Therapeutics News
LifeMine Therapeutics is reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere. Through its...
The deal also includes undisclosed milestones and royalties. Greg Verdine LifeMine FOG Pharma. Gregory Verdine, Ph.D. (LifeMine Therapeutics).
LifeMine Therapeutics, a company that analyzes fungal genomes to find molecules that have potential as new medicines, has raised $175 million in...
LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics, today announced a $50 million Series B financing from leading life sciences investors. The financing was led by Rick Kl ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics, today announced a $50 million Series B financing from leading life sciences investor ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $32.9M | 146 | 3% | N/A |
#2 | $22.6M | 146 | 8% | N/A |
#3 | $51M | 146 | 16% | $38.7M |
#4 | $28.9M | 146 | 15% | N/A |
#5 | $46.9M | 147 | 1% | N/A |
LifeMine Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2017-09-19 | $55.0M | A | WuXi Healthcare Ventures | Article |